TP53 and angiosarcoma: This is clearly seen in canine hemangiosarcoma and osteosarcoma, both TMB-H (Fig. 6a), and with TP53 mutated in 59 and 50% of their tumors, respectively (Fig. 3a; Supplementary Data 3).